Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) has been assigned an average rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.83.
A number of research analysts recently commented on CLSD shares. Chardan Capital began coverage on Clearside Biomedical in a report on Wednesday, August 21st. They issued a “buy” rating and a $6.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Clearside Biomedical in a research note on Tuesday, August 27th. Finally, Oppenheimer initiated coverage on shares of Clearside Biomedical in a report on Tuesday, June 25th. They set an “outperform” rating and a $5.00 price objective for the company.
Check Out Our Latest Report on CLSD
Clearside Biomedical Price Performance
Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.25 million. During the same quarter in the previous year, the company posted ($0.15) EPS. Equities analysts anticipate that Clearside Biomedical will post -0.56 earnings per share for the current year.
Institutional Trading of Clearside Biomedical
A number of large investors have recently made changes to their positions in CLSD. SG Americas Securities LLC purchased a new position in Clearside Biomedical in the first quarter worth about $49,000. International Assets Investment Management LLC purchased a new position in shares of Clearside Biomedical in the 1st quarter worth approximately $57,000. XTX Topco Ltd increased its position in shares of Clearside Biomedical by 172.2% during the 2nd quarter. XTX Topco Ltd now owns 54,313 shares of the company’s stock valued at $71,000 after purchasing an additional 34,359 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Clearside Biomedical during the 2nd quarter valued at $368,000. Finally, Renaissance Technologies LLC lifted its position in Clearside Biomedical by 6.6% in the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company’s stock worth $757,000 after buying an additional 35,900 shares during the last quarter. 18.75% of the stock is currently owned by institutional investors.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
- Five stocks we like better than Clearside Biomedical
- The 3 Best Blue-Chip Stocks to Buy Now
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- What Are Dividend Achievers? An Introduction
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.